News

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
A revolutionary new preventative medicine that protects against the HIV virus has just been approved by the U.S. Food and ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.
HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need - FDA approval paves the way for the ...
The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...